Friedrich-Alexander-Universitat Erlangen-Nürnberg

University of California

Leland Stanford Junior University

Other

The University of North Carolina at Chapel Hill

Universitätsklinikum Erlangen

Peter Gmeiner

Brian K Kobilka

Aashish Manglik

Brian K Shoichet

Daniela Gisela Dengler

Bryan Leo Roth

Henry Lin

Miriam Ruberg

Harald Huebner

Roger K Sunahara

Carsten Korth

Stefan Löber

Ralf Klingenstein

Jeremy Shonberg

Anne Stößel

Ashutosh Banerjee

Markus Stanek

Dorothée Möller

Olaf Prante

Simone Maschauer

Mary Joyce Clark

Luis Maul

Torsten Kuwert

Anat Levit

Harald Hübner

Harald Hüebner

Aspects of the present disclosure include conformationally restricted analogs of catecholamine type compounds (e.g., isoprenaline, adrenaline, noradrenaline) which activate &#x3b2;2AR with high selectivity over &#x3b2;1AR. The subject beta-2 selective adrenergic receptor agonist compounds may serve as bronchiodilators and find use in the treatment of a variety of bronchoconstrictive diseases and conditions. Also provided are compositions and methods for treating preterm labor. A method of treating acute asthma including administration of a subject compound to a subject in need thereof is provided. The subject method can provide for reduced undesirable side effects associated with non-selective &#x3b2;-adrenergic receptor agonism, such as inotropic and chronotropic effects that leads to elevated blood pressure. The compounds can also be used to prevent or treat heart failure. Kits and compositions for practicing the subject methods are also provided.

Beta-2 selective adrenergic receptor agonists

Described herein, inter alia, are compositions and methods for modulating mu opioid receptor activity.

Mu opioid receptor modulators

The present invention describes a compound of formula (I) which can be used in the diagnosis, treatment or prevention of neurotensin receptor-related conditions such as tumors and hematological malignancies. 

Diagnosis, treatment and prevention of neurotensin receptor-related conditions

MU opioid receptor modulators

The present application relates generally to amino tetraline derivative compounds and methods of use, specifically, embodiments including compounds of formula (I) described herein, pharmaceutically acceptable salts and solvates. More specifically, this application relates to amino tetraline derivative compounds and uses of such compounds producing medicaments for the treatment of various disease and conditions including movement disorders and disorders of the central nervous system.

Aminotetraline derivatives

The present application relates to compounds of formula (I): and pharmaceutically acceptable salts and solvates thereof, wherein the substituents are as defined herein, compositions containing such compounds and the uses of such compounds in producing medicaments for the treatment of various diseases and conditions, such as of the central nervous system. 

The invention relates to compounds according to general formula (1) and/or their enantiomers, diastereomers as well as their pharmaceutically compatible salts, and to the use thereof for producing a medicament suited for treating diseases associated with misfolded proteins.

9-amino-acridine derivatives and their use for eliminating misfolded proteins

Growing community of inventors

Buckenhof, Germany

Peter Gmeiner